Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

Esperion Therapeutics, Inc. (ESPR) had Revenue of $332.31M for the most recently reported fiscal year, ending 2024-12-31.

Quarterly Annual

Figures for fiscal year ending 2024-12-31

Income Statement Financials
Revenue	$332.31M
Net Income	$-51.74M
Cost of Goods Sold	$68.60M
Gross Profit	$263.71M
Operating Expenses	$277.91M
Operating Income	$54.40M
Non-Operating Income/Expense	$-106.15M
Pre-Tax Income	$-51.74M
Normalized Pre-Tax Income	$-51.74M
Income after Taxes	$-51.74M
Income from Continuous Operations	$-51.74M
Consolidated Net Income/Loss	$-51.74M
Normalized Income after Taxes	$-51.74M
EBIT	$54.40M
EBITDA	$55.96M
Weighted-Average Shares Outstanding (Basic)	187.18M
Weighted-Average Shares Outstanding (Diluted)	187.18M
Earnings per Share (EPS) (Basic)	$-0.28
Earnings per Share (EPS) (Diluted)	$-0.28
Balance Sheet Financials
Current Assets	$338.00M
Property, Plant, and Equipment	$0.25M
Long-Term Assets	$5.82M
Total Assets	$343.82M
Current Liabilities	$246.23M
Long-Term Debt	$237.72M
Long-Term Liabilities	$486.31M
Total Liabilities	$732.54M
Common Equity	$-388.72M
Tangible Shareholders Equity	$-388.78M
Shareholders Equity	$-388.72M
Common Shares Outstanding	195.85M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-23.65M
Cash Flow from Investing Activities	$-0.32M
Cash Flow from Financial Activities	$86.48M
Beginning Cash	$82.25M
End Cash	$144.76M
Increase/Decrease in Cash	$62.51M
Stock-Based Compensation	$11.99M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	1.37
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	-1.57
Debt to Equity Ratio	-0.75
Gross Margin	79.36%
Operating Margin	16.37%
EBIT Margin	16.37%
EBITDA Margin	16.84%
Pre-Tax Profit Margin	-15.57%
Profit Margin	-15.57%
Free Cash Flow	$-23.97M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.97
Inventory Turnover	0.73
Receiveable Turnover	4.15
Days Sales in Receivables	88.02
Return on Equity	13.31%
Return on Tangible Equity	13.31%
Return on Assets	-15.05%
Return on Investments	34.27%
Book Value Per Share	$-1.98
Free Cash Flow per Share	$-0.13
Operating Cash Flow per Share	$-0.13

Data from Zacks Investment Research, Inc.